![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SoniVie’s Intravascular Ultrasound System Gets Breakthrough Designation for Renal Artery Denervation
SoniVie’s Intravascular Ultrasound System Gets Breakthrough Designation for Renal Artery Denervation
December 11, 2020
The FDA has awarded SoniVie with a Breakthrough Device designation for its Therapeutic Intra-Vascular Ultrasound (TIVUS), a device being developed to treat a number of hypertensive disorders.
The designation was granted for renal artery denervation for the treatment of resistant hypertension, defined as blood pressure that remains above 140/90 mmHg despite the use of three antihypertensive drugs of different classes, one of which must be a diuretic.
The minimally invasive device uses high-frequency, nonfocused ultrasound to ablate nerves in the renal artery, causing a reduction in nerve activity and decreasing blood pressure.
Upcoming Events
-
21Oct